A study showed that axitinib, a small molecule tyrosine kinase inhibitor that targets VEGFR, attenuated VEGF-D upregulation in serum and lung lining fluid, as well as inhibited Tsc2-null lung lesion growth and abnormal lymphangiogenesis in a mouse model of LAM (42). The gene discussed is TSC2; the disease is lymphangioleiomyomatosis.